What CRO job ads actually demand now

We read what the current postings require for CRA, data management, and biostatistics roles. The specific systems and skills that show up again and again are the ones worth building.

Read the piece →

Risk-based monitoring and E6(R3): is the CRA travel role really shrinking?

The updated good clinical practice standard makes centralized monitoring a core pillar. What that means for source verification, site visits, and the future of the road-warrior CRA.

Read the piece →

FDA's AI guidance, explained for people who run trials

The January 2025 draft credibility framework in plain terms: the two-factor risk test, the seven steps, what is in scope, and what you actually have to produce.

Read the piece →

A warning letter is a CAPA avalanche. Guess who does the digging.

The FDA letter is one page. The work it triggers is months. A field guide to what actually happens after a 483 or a warning letter, and who absorbs it.

Read the piece →

Protocol, consent, records: the three failures behind most clinical citations

Strip the FDA's clinical warning letters down and almost all of them come back to three basics. What they are, real examples of each, and how sites actually lose them.

Read the piece →

How to look up what any employer actually filed to pay

The government publishes the real wages employers committed to for visa-sponsored roles. Here is how to find what a specific company filed for your title before you negotiate.

Read the piece →

Book-to-bill: the one number that predicts CRO hiring

Public CROs report a metric every quarter that forecasts their revenue years out, and their hiring with it. Here is how to read it before your employer's next reorg.

Read the piece →

The FDA inspection that can end a trial site

The FDA's bioresearch monitoring program inspects clinical trials, and the outcome is graded in three letters. What NAI, VAI, and OAI mean, and why the count is rising.

Read the piece →

Look up your own program before it looks you up

The same public registry that tracks the whole industry tracks your specific trial. Here is how to read it as an early-warning system for your own job.

Read the piece →

How big is a trial, really? The enrollment numbers behind your workload

Most trials are far smaller than the headline mega-studies. The registry shows the median completed industry trial enrolled about 70 patients. What size means for the work.

Read the piece →

If WARN cannot see your layoff coming, what can?

The public filings miss most clinical research cuts. Here are the earlier, quieter signals that actually predict a reduction, and how to read your own situation before the email arrives.

Read the piece →

Remote, hybrid, or on the road: what clinical research roles actually require

Job ads say remote. Travel percentages say otherwise. A function-by-function look at which clinical research roles are genuinely home-based and which just say so.

Read the piece →

Sunday night report writing: does it ever stop?

Visit-report turnaround expectations follow CRAs home, and the techniques that circulate (report skeleton before the visit, dictation on the drive back, batching) only soften it. The recurring worker-side claim is that the math of site load, not writing technique, is the real problem. What actually worked for you, if anything?

What a monitoring visit actually is

For the people adjacent to clinical research, and the people about to join it: the real anatomy of the CRA's defining ritual.

Read the piece →